Kamada to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Kamada’s CEO will present at the H.C. Wainwright Global Investment Conference, with a webcast and 30-day replay available to investors.

Rhea-AI Summary

Kamada (KMDA) will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel in New York. CEO Amir London is scheduled to present on Tuesday, September 15, 2026, at 2:30 p.m. Eastern Time and will also be available for one-on-one investor meetings arranged via H.C. Wainwright representatives.

A live webcast and 30-day audio replay of the presentation will be accessible through a specific event link and in the investor relations section of Kamada’s website under Events & Presentations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

REHOVOT, Israel, and HOBOKEN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will participate and present at the H.C. Wainwright 28th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel.

Mr. London is scheduled to present at the conference on Tuesday, September 15, 2026, at 2:30 p.m. Eastern Time. In addition to the presentation, Mr. London will be available for one-on-one investor meetings throughout the conference. Investors that are interested in arranging a meeting should contact their H.C. Wainwright representative.

A live webcast and audio archive of the event may be accessed here (the full link appears below as well) and through the investor relations section of Kamada’s website at https://www.kamada.com/events-presentations/. The recording replay will be available for 30 days.

Link to webcast: https://journey.ct.events/view/e756f52e-3889-4b68-aca5-aaf0b71df91d

About Kamada

Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately 38% of the outstanding ordinary shares. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth of its commercial portfolio, including continued investment in the commercialization and life cycle management of its proprietary products, consisting of six FDA-approved specialty plasma-derived products: KEDRAB®, GLASSIA®, CYTOGAM®, VARIZIG®, WINRHO SDF® and HEPAGAM B®, as well as KAMRAB®, and two equine-based anti-snake venom products. Second, distribution of third-parties pharmaceutical products in Israel & the MENA region through in-licensing partnerships, including the launch of several biosimilar products in Israel. Third, the Company is ramping up its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three FDA-approved operating plasma collection centers in the United States, in Beaumont, Houston, and San Antonio, Texas. Fourth, the Company aims to secure new mergers and acquisitions, business development, in-licensing and/or collaboration opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term profitable growth. The Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need.

CONTACTS:

Chaime Orlev
Chief Financial Officer
IR@kamada.com

Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com

FAQ

When and where will Kamada’s presentation take place during the conference?

Amir London is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 2:30 p.m. Eastern Time at the Lotte New York Palace Hotel.

How can investors arrange one-on-one meetings with Kamada during the event?

Investors interested in one-on-one meetings with Amir London during the conference should contact their H.C. Wainwright representative to arrange a meeting.

How can the webcast and replay of Kamada’s presentation be accessed?

The live webcast and audio archive can be accessed via the provided event link and through the investor relations section of Kamada’s website at https://www.kamada.com/events-presentations/. The recording replay will be available for 30 days.